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Abstract
Background: The economic implications of major system change are an important component of the decision to
implement health service reconfigurations. Little is known about how best to report the results of economic evaluations
of major system change to inform decision-makers. Reconfiguration of acute stroke care in two metropolitan areas in
England, namely London and Greater Manchester (GM), was used to analyse the economic implications of two different
implementation strategies for major system change.
Methods: A decision analytic model was used to calculate difference-in-differences in costs and outcomes before and
after the implementation of two major system change strategies in stroke care in London and GM. Values in the model
were based on patient level data from Hospital Episode Statistics, linked mortality data from the Office of National
Statistics and data from two national stroke audits. Results were presented as net monetary benefit (NMB) and using
Programme Budgeting and Marginal Analysis (PBMA) to assess the costs and benefits of a hypothetical typical region
in England with approximately 4000 strokes a year.
Results: In London, after 90 days, there were nine fewer deaths per 1000 patients compared to the rest of England
(95% CI –24 to 6) at an additional cost of £770,027 per 1000 stroke patients admitted. There were two additional deaths
(95% CI –19 to 23) in GM, with a total costs saving of £156,118 per 1000 patients compared to the rest of England. At a
£30,000 willingness to pay the NMB was higher in London and GM than the rest of England over the same time period.
The results of the PBMA suggest that a GM style reconfiguration could result in a total greater health benefit to a region.
Implementation costs were £136 per patient in London and £75 in GM.
Conclusions: The implementation of major system change in acute stroke care may result in a net health benefit to a
region, even one functioning within a fixed budget. The choice of what model of stroke reconfiguration to implement
may depend on the relative importance of clinical versus cost outcomes.
Keywords: economic evaluation, stroke, major system change, implementation, cost-effectiveness, programme
budgeting and marginal analysis
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Background
Major system change involves the reorganisation, some-
times called reconfiguration, of services at a regional
level. Hospital centralisation is a form of major system
change where services are reorganised so that a reduced
number of hospitals provide specialist clinical care. A
common service reconfiguration is a hub and spoke
model, where healthcare services provided in specialised
hubs are complemented by a number of smaller services
providing less specialist, complex or intensive care.
In 2010, a major system change of acute stroke services
was implemented in two metropolitan areas in the English
National Health Service (NHS), London (population 8.17
million) [1] and Greater Manchester (GM) (population
2.68 million) [1] with the aim of improving access to high
quality specialist stroke care and thereby improve patient
outcomes. In London, post reconfiguration, all patients
identified as potentially having a stroke were taken by am-
bulance to one of eight hospitals with a designated hyper-
acute stroke unit (HASU), a ward that provides intensive,
dedicated stroke care from a specialist multi-disciplined
team. Patients remained on the HASU for 72 hours before
either being discharged or moved to one of 24 stroke units
[2–6] that provide ongoing care and rehabilitation. In
GM, a similar model was implemented with the exception
that patients with suspected strokes were transferred to a
hyper-acute centre only if the onset time was within the
previous 4 hours.
The centralisations have been associated with a 1.1%
reduction of stroke-related deaths at 90 days in London,
or 168 fewer deaths 21 months after the centralisation,
as well as a reduction in bed days of 1.4 days per patient
in London and 2.8 bed days per patient in Manchester
compared to the rest of England [4].
The centralisation of acute stroke care in GM and
London provides an opportunity to explore the implica-
tions for decision-makers of two different ways of
reporting the results of an economic evaluation of major
system change, in particular contrasting ways of repor-
ting quality adjusted life years (QALYs) versus costs.
Economic evaluations and the decision to implement
major system change
Economic evaluations of the implementation of major
system change and policy initiatives are rare, with no
specific framework-guiding analysis methods [7].
The decision to implement new interventions in
publicly financed healthcare systems that operate within a
fixed budget, as is the case with the NHS, can sometimes
result in a need to weigh up clinical effectiveness and cost.
An intervention shown to be clinically effective may cost
significantly more than current practice. If the new, more
expensive intervention is to be implemented, a decision
may need to be made if (1) the healthcare service will now
treat fewer patients as the cost per patient has now in-
creased, or (2) funds need to be taken from another ser-
vice to finance the cost of the new treatment.
Alternatively, the new service and its clinical effectiveness
may result in cost savings produced elsewhere and hence
the total cost per patient is reduced.
To help payers and policy-makers decide whether they
should implement a new technology or service there are a
number of types of economic analysis that can be under-
taken. Within the English NHS the most common type of
economic analysis for evaluating if a new technology should
be implemented is to report the incremental cost per
QALY gained of current or best practice compared to a
new technology. QALYs are the preferred unit of reporting
effectiveness of the National Institute for Health and Care
Excellence (NICE), the NHS government body responsible
for evaluating new technologies and recommending their
implementation, given that QALYs are a combination of
both mortality and morbidity over time weighted for the
general public preferences for health outcomes [8]. If the
incremental cost to the NHS of a QALY gained as a result
of the new technology is less than £20,000 per QALY, in
87% of cases, NICE will recommend that the new techno-
logy is made available to patients in the NHS [9]. However,
the use of the £20,000 threshold has been criticised given
that the cost to produce an additional QALY in the NHS is
£12,936. As a result, approval of new technologies using a
threshold higher than £12,936 risks displacing technologies
where the cost to produce an additional QALY is less and
hence more efficient [9].
An alternative approach for evaluating the impact of
implementing new technologies or services is Programme
Budgeting and Marginal Analysis (PBMA). PBMA com-
pares the additional benefit achieved per pound spent on a
technology or service, A, compared to another service or
technology, B, where B may be current practice or even an
alternative healthcare service. The benefit of PBMA is that
it facilitates the evaluation of benefit of A compared to B
across programmes of work and within a fixed budget [10].
The aim of this paper is to report the economic impli-
cations of the reconfiguration in London and GM
compared to metropolitan areas in the rest of England.
The information will be reported in a way to aid with
the decision to implement different reconfigurations of
acute stroke care using different types of analysis (1)
reporting the incremental cost per QALY gained as
recommended by NICE and (2) using a hypothetical
region with a fixed budget and PBMA.
Methods
Overview
We estimated difference-in-differences in costs, inclu-
ding the cost of implementation, and clinical outcomes
to evaluate the effect of the reconfigurations in London
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and GM on costs, mortality and QALYs compared to
metropolitan areas in the rest of England. Metropolitan
areas were chosen so that population density and blue
light ambulance travel time to hospital were as compar-
able as possible with London and GM. The analysis was
undertaken with a cost perspective of the English NHS
and personal social services. Eight decision analytic
models were developed, each with 1000 hypothetical
stroke patients. The time periods were as in Morris et al.
[4] as described below.
(1). London before the reconfiguration (January 2008
to January 2010)
(2). London after the reconfiguration (July 2010 to
March 2012)
(3). The rest of England (Metropolitan only),
excluding GM for the same time period as (1)
(4). The rest of England (Metropolitan only),
excluding GM for the same time period as (2)
(5). GM before the reconfiguration (January 2008 to
November 2008)
(6). GM after the reconfiguration (April 2010 to
March 2012)
(7). The rest of England (Metropolitan only),
excluding London for the same time period as (5)
(8). The rest of England (Metropolitan only),
excluding London for the same time period as (6)
Total costs and QALYs per 1000 patients were calcu-
lated for each of the eight models at 90 days and 10
years after admission, using a discount rate of 3.5% for
costs and QALYs [8]. Costs are for the year 2013/2014
and are in British Pounds (£). We report the difference
in costs and QALYs for (1) and (2) compared to (3) and
(4), and the difference in costs and QALYs for (5) and
(6) compared to (7) and (8).
Data
We used routinely collected hospital data (Hospital
Episode Statistics (HES)), audit data (National Senti-
nel Stroke Clinical Audit 2008, Stroke Improvement
National Audit Programme (SINAP)) and data from
the published literature to construct the model.
Table 1 provides details on the number of stroke
patients in each dataset.
Table 1 Data sources and numbers
GM England comparison London England comparison
Before After Before After Before After Before After
HES 3503 7685 42,880 95,244 15,276 15,023 100,511 84,801
Age, mean 74.3 73.9 75.8 75.3 73 73.3 75.7 75.3
> 75, % 56% 53.6% 61.2% 59.18% 54.3% 54.4% 60.7% 52.3%
Female, % 52.6% 50.4% 53.0% 53.2% 51% 49.8% 53.0% 52.2%
White British ethnic group, % 82.9% 84.2% 82.4% 86.5% 58.5% 55% 83.9% 86.5%
Intracerebral haemorrhage, % 11.5% 11.7% 13.0% 12.7% 15.7% 14.8% 12.9% 12.7%
Cerebral infarction, % 61.6% 64.4% 62.7% 71.3% 68.9% 76.1% 64.4% 71.2%
Stroke not specified, % 26.9% 23.9% 24.3% 16.1% 15.4% 9.1% 22.7% 15.8%
Charlson index, mean score 2.0 2.0 1.9 1.9 2.0 2.0 1.9 1.9
Most deprived fifth, % 8.4% 10.3% 17.1% 17.6% 12.6% 13.2% 17.3% 17.6%
SINAP 10,295 9044 16,553 9044
Age, mean 73.2 73.6 72.7 73.6
> 75, % 50% 51% 50% 51%
Female, % 51% 51% 49% 51%
Intracerebral haemorrhage, % 11% 11% 11% 11%
Cerebral infarction, % 89% 89% 89% 89%
Sentinel 653 537 1541 537
Age, mean 74.5 74.6 73.3 74.6
> 75, % 55% 53% 51% 53%
Female, % 52% 52% 50% 52%
Intracerebral haemorrhage, % 13% 11% 14% 11%
Cerebral infarction, % 87% 89% 86% 89%
GM Greater Manchester, HES Hospital Episode Statistics, SINAP Stroke Improvement National Audit Programme
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The HES data only contained patients with a primary
diagnosis of stroke, as defined by ICD-10 codes I61 (in-
tracerebral haemorrhage), I63 (cerebral infarction) and
I64 (stroke, not specified as haemorrhage or infarction),
and from metropolitan areas using the urban/rural clas-
sification for England [11]. It is linked to data from the
Office of National Statistics vital statistics to obtain date
of death [12].
Sentinel was a national biennial audit that collected data
on the first 60 strokes across participating hospitals for
the period April to August each year. Data from the 2008
Sentinel audit were used [13]. SINAP was a national audit
of stroke care across participating acute hospitals in
England providing data from all identified patients in
participating hospitals from July 2010 to 2012 [14].
The South London Stroke Register (SLSR), a
population-based stroke prospective registry recording all
first-ever strokes in patients of all ages living in an area of
South London [15], was used to calculate changes in
disability before and after the reconfigurations.
Further details on the datasets used can be found in
Morris et al. [4] for HES data, Ramsay et al. [5] for
Sentinel and SINAP, and Hunter et al. [3] for SLSR. Data
were analysed using STATA 13.
Model structure
Each of the eight models has two components:
(1).A 90-day discrete event simulation of daily acute
hospital ward movements, discharge destinations
and mortality using data from HES, Sentinel and
SINAP (Fig. 1).
(2).A 10-year Markov model [16] with 90-day cycles
using information from the 90-day model plus HES,
the SLSR and published data to calculate costs and
QALYs (Additional file 1: Figure S1).
All patients enter the 90-day model as an admission to
hospital following a stroke. The proportion of patients in
each health state in the first cycle of the 10-year model
is determined by the final destination of patients in the
90-day model, including still on an acute hospital ward.
The 90-day discrete event simulation is also used for 90-
day costs and outcomes of hospitalisation following
recurrent strokes in the 10-year Markov model.
The flow for the 90-day model is illustrated in Fig. 2,
excluding the state of death – patients have a probability
of death every day of the 90-day model regardless of
where they are in the model. The same flow is used for
all eight models and is different to the stylised diagrams
in Fig. 1. This is because, following the reconfigurations,
despite the fact that patients should only have been ad-
mitted to a HASU in London and to a HASU if the
stroke had occurred within 4 hours prior to admission
and a District Stroke Centre if it had occurred more
than 4 hours prior in GM, data from SINAP show only
whether the first ward of admission was a stroke unit or
not and do not provide information on the specific type
of stroke unit [5].
The model was developed in Microsoft Excel 2010.
Mortality
Mortality at 72 hours, 30 days and 90 days was calculated
using the same data and a similar method to Morris et al.
Fig. 1 Stroke pathway in London and Greater Manchester: before and after reconfigurations. ASU acute stroke unit, HASU hyper acute stroke unit,
DSC district stroke centre
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[2], including coefficients to adjust for differences between
regions in age, sex, ethnicity, deprivation (index of mul-
tiple deprivation quintile) [17], and co-morbidities using
the Charlson index [18]. Random effects for provider were
also applied to the model. Two logistic regression models
were fitted to the HES data; one for London and the rest
of England excluding GM and one for GM and the rest of
England excluding London. Values for the models are re-
ported in Additional file 1: Table S1 and further details for
the calculation of transition probabilities are provided in
Additional file 1: Methods S1.
Length of stay (LOS) and discharge destination
HES data were used to calculate the daily probability of
discharge from acute hospital and discharge destination
using a parametric survival model and Weibull distribu-
tion [16]. Two analyses, London (analyses 1 to 4 in over-
view) and GM (analyses 5 to 8 in overview), were run with
the same adjustments as the mortality models (Additional
file 1: Table S3). We assumed the probability of discharge
was the same regardless of ward type as there is no infor-
mation in HES on ward-specific LOS.
The method for calculating ward movements and
discharge destination is provided in Additional file 1:
Methods S2 and Tables S4 and S5.
10-year model
The model is described in Additional file 1: Figure S1 and
model inputs in Additional file 1: Table S4. The possible
states in the 10-year model are (1) home and in one of five
health states based on the Barthel index, a measure of
functional independence, where 0 is no functioning and
20 is fully functional (0–4, 5–9, 10–14, 15–19 and 20); (2)
residential care or nursing home; (3) recurrent stroke and
in hospital < 90 days; (4) recurrent stroke and in hospital
> 90 days; and (4) dead.
The probability of patients discharged to community
hospital or home being admitted to residential care or
nursing home was taken from SLSR (Additional file 1:
Table S4).
The probability that patients had a recurrent stroke
following discharge was calculated using HES data and
parametric survival analysis. A Weibull model [16] was
used to give differential probabilities over time with prob-
abilities calculated for 90-day cycles. Models were adjusted
using the same methodology as above and were calculated
for GM versus the rest of urban England, excluding
London, and London compared to the rest of urban
England excluding GM (Additional file 1: Table S4).
The probability of recurrent stroke for patients
discharged in residential care or a nursing home was
calculated from HES for patients discharged to resi-
dential care only.
The 10-year model takes into account the health and
well-being of patients discharged from acute care using
the Barthel index, with patients divided into the five
Barthel states given above. The proportion of patients in
each Barthel state and movement between them has
been taken from the SLSR with different rates before
and after (Additional file 1: Table S4). No data are
available for Barthel indexes or any other measure of
functioning or quality of life for GM or the rest of
England before the reconfiguration. As a result, it is not
possible to evaluate the impact of the reconfigurations
on functioning or quality of life in GM or compare the
changes that occurred in London with what happened
over the same period in the rest of England. For the pur-
pose of the model and calculating QALYs, the conserva-
tive assumption was made that the same improvements
were seen in GM, the rest of England and London as
were seen in the SLSR.
Probability of dying while in a care home was updated
to Gordon et al. [19] as the most recent estimate available
in the literature.
Unit costs
Details of unit costs are given in Table 2. The cost of
transfer has not been included as transfer costs were
included in the additional cost of the HASU [6].
Fig. 2 The 90-day discrete event simulation model structure. ITU
intensive therapy unit, CCU coronary care unit
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Costs of implementation
We undertook reviews of documentary evidence to iden-
tify the costs of implementing the reconfigurations in
London and GM, including one-off financial investments
to improve services, research to investigate the optimal
configuration of services, and public and staff
consultations.
QALYs
QALYs were calculated using Barthel index from the
SLSR and the methods described in Hunter et al. [3].
Utility scores were applied to each ward and discharge
location and calculated as a daily rate for the 90-day
model and each location for the 10-year model and
calculated as a 90-day rate. Details on utility scores are
provided in Additional file 1: Table S5.
Cost-utility analysis
A difference-in-differences approach was used to com-
pare cost and mortality at 90 days and costs and QALYs
at 10 years; we compared costs, mortality and QALYs in
London before and after the reconfiguration outcomes
and costs over the same period in the rest of England
(excluding GM). The same analysis was then conducted
for GM (excluding London). Mortality and LOS was ad-
justed for differences between London, GM and the rest
of England in age, sex, co-morbidities (Charlson Index
[18]), stroke type and level of deprivation [17].
Net monetary benefit (NMB) is defined as total QALYs
multiplied by a willingness to pay (WTP) for a QALY
minus costs. Incremental NMB is calculated for London
before the changes compared to after (models 1 and 2)
and England, excluding GM, for the same time periods
(models 3 and 4) for a range of values of WTP for a
QALY gained (£0 to £100,000). If the incremental NMB
was higher for London than the rest of England the
London reconfiguration was then considered to be cost-
effective. The same was performed for GM.
PBMA
The budget for delivering acute stroke care in the hypo-
thetical example was set at £40 million pounds per year,
equating to the approximate amount required to treat
4000 strokes a year, close to the average number of
admissions to acute hospital with a diagnosis per year in
a region of approximately 3 million inhabitants in
England [20]. Using the goal seek command in Excel, we
calculated the number of patients with stroke treated in
1 year and total QALYs at 1, 5 and 10 years if a region
has a fixed budget of £40 million per year. This was cal-
culated before and after reconfiguration and differences
between reconfigured areas and the rest of metropolitan
England were compared. The cost per patient of imple-
mentation was included in the analysis.
Probabilistic sensitivity analysis
Probabilities were applied to the model using the me-
thodology given in Briggs et al. [16]. For costs, a gamma
distribution was used with 25% variation around the
mean. A total of 5000 iterations of the eight models were
run and costs, mortality and QALYs over 10 years and
90 days were captured. The percentage of iterations
Table 2 Cost inputs for 90-day and 10-year model
Cost input Cost per event/per day Reference
HASU London uplift tariff day 1 £665a London Stroke Strategy [6]
HASU London uplift tariff days 2–3 £399a London Stroke Strategy [6]
GM Best Practice tariff per day for first 72 hours if
admitted to hyper-acute care
£580 2014/2015 DH National Payment system [30]
GM Guidance [31]
Stroke unit per bed day cost £238 2013/2014 Reference Costs [32]
Medical assessment ward £187 2013/2014 Reference Costs [32]
General medical ward £218 2013/2014 Reference Costs [32]
Intensive care or critical care unit £1578 2013/2014 Reference Costs [32]
Other ward not otherwise specified £203 2013/2014 Reference Costs [32]
Nursing home £105 PSSRU 2014 [33]
Private nursing home £107 PSSRU 2014 [33]
Transfer to other NHS hospital (not acute) £100 PSSRU 2014 [33]
Thrombolysis £828 2014/2015 DH National Payment system [30]
90-day costs Barthel score 20–10 £459 Franklin et al. 2014 [34]
90-day costs Barthel score 0–9 £1926 Franklin et al. 2014 [34]
90-day costs residential care or nursing home £10,647 Gordon et al. 2014 [19]
aConverted to 2013/2014 prices using Hospital and Community Health Services inflation index [33]
DH Department of Health, GM Greater Manchester, HASU hyper-acute stroke unit
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where London or GM had a higher NMB than the rest
of England for a specific WTP for a QALY gained were
recorded and shown on a cost-effectiveness acceptability
curve. Additionally, 95% confidence intervals were calcu-
lated using the standard deviation of the 5000 iterations
of the model.
Other sensitivity analyses
To test assumptions made in the model, five sensitivity
analyses were conducted. Details of the sensitivity ana-
lyses conducted are reported in Additional file 1:
Methods S1.
Results
Base case
At 90 days, London had a reduced risk of mortality com-
pared to the rest of England before versus after the recon-
figuration. Per 1000 strokes, the adjusted number of
deaths in London at 90 days was 100 before the reconfig-
uration and 75 after, thus a reduction of 2.7 percentage
points in the number of deaths. During the same period in
England there was an adjusted reduction in deaths of 1.8
percentage points (114 deaths before compared to 97
deaths after) (Table 3). This represents a relative reduction
in deaths in London compared to the rest of England of
0.9% or 9 deaths per 1000 patients. In 90% of iterations of
the model, London had a greater reduction in deaths after
the reconfigurations than the rest of England. Compared
to the rest of England, there was no reduction in deaths in
GM at 90 days. Both areas had a reduction in LOS relative
to the rest of England, namely of 2 days less in GM and
0.6 days less in London.
At 10 years, both reconfigurations resulted in more
QALYs compared to their Rest of England comparator
(Table 4). London resulted in 58 more QALYs at 10
years per 1000 patients at an additional cost of
£1,014,363. This is equivalent to an incremental cost
effectiveness ratio of £17,452; hence, at a WTP for a
QALY gained of £20,000, the changes in London have a
higher NMB than the rest of England over the same
time period. However, the incremental cost effectiveness
ratio is greater than the average cost to produce a QALY
in the NHS of £12,936, suggesting that some displace-
ment of services and a net QALY loss may have
occurred. At 10 years, the reconfigurations that occurred
in GM dominate what happened in England over the
same time period in that there are more QALYs (18
QALYs per 1000 patients over 10 years compared to the
rest of England) and less costs (−£470,848 per 1000
patients compared to the rest of England over 10 years).
Cost-effectiveness acceptability curve
The probability that the changes that occurred in GM as
a result of the reconfigurations had a higher NMB than
what occurred in England over the same time period
peaked at a WTP for a QALY gained of £7000 and 82%
probability (Fig. 3). GM had a higher probability of being
cost-effective than London at a WTP for a QALY gained
of values less than £39,000. GM had a higher probability
of being cost-effective at lower values of WTP for a
QALY as 35% of iterations of the difference in costs and
QALYs in GM compared to England over the same time
period fell in the south-west quadrant of the cost-
effectiveness plane (Fig. 4); thus, the changes in GM cost
less than in the rest of England but there was only a 60%
chance that there was also a reduction in mortality com-
pared to the rest of England. For London, the majority
of iterations of the model (80%) fell in the north-east
quadrant for London, where London cost more but also
had a higher probability that there was an improvement
in mortality (81%).
Sensitivity analyses
The results of the sensitivity analyses are reported in
Additional file 1: Tables S6 and S7. None of the sensitiv-
ity analyses changed the conclusions drawn as a result of
the analysis, other than the observation that, once the
cost of a HASU increased by 50% per night, the London
reconfigurations were no longer cost-effective at a WTP
of £20,000 per QALY. If it was assumed that improve-
ments in functioning (Barthel index) only occurred in
London and GM as a result of the reconfiguration but
not in the rest of England, there was a 97% chance in
both London and GM that the reconfigurations be cost-
effective at 10 years at a WTP of £20,000 for a QALY
(Additional file 1: Figure S2).
Costs of implementation
In addition to the funding for the increased tariff, add-
itional one-off financial investments were made to bring
about the reconfigurations in London and GM. It was
estimated that an investment of £9 million was made in
London to meet the requirements for the new HASUs
and stroke units, covering capital, equipment and prem-
ises refurbishment [21]. The cost of the tariff uplift has
been included in the analysis already as the increased
cost per bed day in a HASU. In 2014/2015, there were
6641 people admitted to hospital with a primary diagno-
sis of stroke in London [20]. Assuming that the London
model will continue to be in place for the next 10 years,
and a constant rate of admission for stroke, the cost of
implementation works out to £136 per patient admitted
with stroke over this period. In GM, it was estimated
that an initial investment of £2.79 million was required
for similar items [22]. In 2014/2015, there were 3732
people admitted to hospital with a primary diagnosis of
stroke in GM [20]. Making the same assumptions as for
London, the cost per patient of the reconfigurations in
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GM was £75 per patient admitted. Other costs are likely
to have been incurred in both London and GM to pay
for research to identify the optimal configuration of ser-
vices, and to consult staff and public, but evidence of
these costs is not available.
QALY production for a fixed budget of £40 million
The results of the analysis comparing total strokes
treated and total QALYs at 1, 5 and 10 years for a fixed
yearly budget of £40 million are reported in Table 5. We
estimated 75 additional QALYs over 10 years as the
result of the centralisation of GM acute stroke care
compared to changes that occurred in the rest of
England for the same time period for a fixed yearly
budget of £40 million. Centralisation of London services
may have resulted in a net loss of 720 QALYs over 10
years. The lower number of estimated QALYs is a result
of a lower volume of patients that may be treated for the
fixed budget.
Discussion
The implementation of major system change in both
London and GM models resulted in a NMB compared
to changes that occurred over the same time period
elsewhere in England at 10 years at a threshold of
£20,000–£30,000 for a QALY. The GM model was cost
saving at 10 years, but did not result in the same health
benefits as the London model; hence, for higher values
of WTP for a QALY, London had a higher probability of
being cost-effective.
Fig. 4 Difference-in-difference cost-effectiveness plane of the adjusted difference in 10-year costs and QALYs between London before and after
reconfigurations minus the difference in England over the same time period, and the difference in costs and QALYs in GM compared to England
over the same time period
Fig. 3 Cost-effectiveness acceptability curve of the probability that the reconfigurations in London and GM resulted in a higher NMB compared
to England over the same time period
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If the value for money of the centralisation of acute care
is tested in the context of PBMA using a finite budget of
£40 million per year (approximate budget required for
4000 stroke admissions per year) and choosing the model
that produces the largest number of QALYs, the GM
model may be preferred based on the QALYs produced at
5 and 10 years. Over time, the cost of treating strokes in
metropolitan areas in England has increased everywhere,
but clinical outcomes have also improved. As a result,
even though fewer people can be treated for a stroke
within the same budget envelope, the resulting total
QALYs (health benefits) may still be greater.
Reporting the results of economic evaluations to
decision-makers
The aim of this study was to present the results of the
cost-utility analysis in two contrasting ways, namely (1)
as cost per QALY in line with NICE recommendations
and (2) as a PBMA to reflect a potential real-world
scenario. Within the English NHS, decision-making
based on economic evaluations predominately occurs as
part of NICE technology assessments and guidelines
[23]. As a result, most cost-effectiveness analyses are
conducted using the NICE reference case as their tem-
plate for their methodology and reporting with little
consideration given to whether this is helpful to
decision-makers at regional and local levels [23].
Previous research has identified that improved clinical
outcomes play a key role in the decision to implement
change [23, 24]. Clinicians in particular prefer that
clinical effectiveness is given more weight, arguing for
the needs of the patients [25]. Both the results of the
NMB and the PBMA would recommend that regions
implement the GM model for acute stroke care reconfi-
guration. However, the fact that GM changed aspects of
its delivery of stroke care following evidence of its lack
of clinical impact is a reflection of the important role
that clinical outcomes play. Indeed, this analysis is only
one component of a wider piece of work looking at how
service reconfiguration comes about in acute stroke ser-
vices, with a key emphasis on clinical and organisational
outcomes [2, 4, 5, 24].
When costs are considered at local and regional levels,
these tend to relate to identifying additional resources
for staffing and the costs of new equipment. Potential
disinvestments in other services are rarely considered.
Where value for money is mentioned, it is more
commonly used to refer to cost-savings, and not the cost
per outcome gained more commonly presented in
economic evaluations [23]. Regardless of the potential
benefits of centralisation of services one of the greatest
challenges for commissioners is identifying funding for
the initial upfront cost of reconfiguring services. How-
ever, previous evaluations of major system change have
failed to address the economic implications of different
implementation strategies [7, 24, 26]. As reported in our
other work [24, 27], this may be one of the greatest bar-
riers to major system changes. To help decision-makers,
we have provided as much information as possible on
the potential costs of implementation. However, more
work is required to identify to what extent these
represent additional resource requirements in regards to
additional staffing and equipment.
A systematic review of economic evaluations of
centralisation of specialist services identified that
most economic evaluations lack information that is
sufficiently detailed and transparent to be useful to
decision-makers [7]. As part of our work, we con-
sulted with decision-makers responsible for decisions
about stroke service reconfiguration, including having
them as members on steering groups, as part of our
qualitative work, informal interviews and corres-
pondence [2]. This was done to ensure that we
present information that is useful to decision-makers
Table 5 Total number of strokes treated and total QALYs for a fixed yearly budget of £40 million
Before After Difference Before After Difference DID
London England
Number of strokes treated per year 4001 3522 −480 3959 3736 −222 −257
QALYs 1 year 1560 1608 49 1500 1653 152 −104
QALYs 5 years 8342 8943 602 7946 9026 1080 −479
QALYs 10 years 13,047 14,067 1020 12,382 14,122 1740 −720
GM England
Number of strokes treated per year 3947 3716 −231 4017 3771 −246 15
QALYs 1 year 1470 1619 150 1494 1659 165 −15
QALYs 5 years 7782 8966 1184 7900 9054 1154 30
QALYs 10 years 12,122 14,056 1934 12,304 14,164 1860 75
GM Greater Manchester, QALYs quality adjusted life years, DID difference-in-difference
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and has been a driver in our decision to report the
results as a PBMA. Reporting results over different
time horizons and for a range of outcomes, not just
QALYs, has also been recommended when reporting
results for decision-makers [7, 28]. Previous research
has suggested that decision-makers rarely use QALYs,
preferring hard clinical outcomes instead as they find
them easier to understand [23, 28]. However, we have
chosen to keep with QALYs given these can capture
both mortality and morbidity – an important consi-
deration in stroke care, which aims to improve func-
tioning in addition to extending life. Nevertheless, we
have continued to report mortality and LOS alongside
QALYs given that decision-makers find these out-
comes easier to understand than QALYs and consider
them important outcomes in stroke care.
Another important consideration for reporting the
results is their generalisability and clear communica-
tion of limitations [7, 23]. We have tried to make the
results generalisable by adjusting for key factors that
are likely to differ across regions in our analysis, for
example, age and type of stroke. As part of the
PBMA, we chose a population size that is representa-
tive of the average metropolitan area in England.
However, the analysis is based on major system
change in two metropolitan areas. A key limitation of
this analysis is that the results are not applicable to
rural areas, which may face different challenges in the
centralisation of acute stroke services. In particular,
rural areas will need to address the issue of greater
travel times as a result of reconfiguration and may re-
quire different solutions to address these, for example,
telemedicine, with different costs to consider in
bringing about these changes [4].
Strengths and weaknesses
The key strength of this analysis is that it provides
information to policy-makers about the real-world
implications of the changes made and hence can in-
form policy decisions about major system changes in
the future. It contains information on the upfront
costs of implementation, as well as ongoing costs,
and presents the results both in regards to clinical
effectiveness, but also using PBMA and within the
context of a fixed budget.
A key weakness is that the results are based on
observational, routinely collected hospital data; most
notable are coding errors. For example, in one London
hospital, 3% of 1300 stroke patients had a discharge
destination code for discharge to a mental health
hospital, compared to 0.13% for hospitals across all of
England. It is unlikely that such a large percentage of
patients were being discharged to this location; instead,
it is more likely that the wrong code had been used and
they were being discharged elsewhere. There is no way
to know where and hence the only option was to re-
move the data prior to estimating discharge destination.
It is likely the dataset contains other errors in relation
to discharge destination. However, it was assumed that
those errors would occur equally at random across the
three regions. It is also hard to know how ‘stroke
mimics’, patients presenting with the stroke-like symp-
toms but who do not have a final diagnosis of stroke,
appear in the data. They may be screened out of the
datasets as not having stroke even though they have a
stroke unit admission, or potentially the final diagnosis
is missing from our dataset. It is hard to know from the
data we have what proportion are mimics and what im-
pact they have had on the cost and outcomes for the
care pathway.
The retrospective nature of the study also meant that
limited information was available on the true cost of
implementation. Although data could be obtained from
reports and interviews with stakeholders, some of the
knowledge of the true cost of implementation would
have been lost. This knowledge and the importance of
collecting in-depth data on the cost of implementation
has assisted with the design of other studies [29].
It is important to note that the values reported in
the model for LOS and mortality are values adjusted
for differences between patients within the regions
with regards to age, ethnicity, sex and co-morbidities.
As a result, they do not represent true values per
1000 or 4000 patients but adjusted values to allow for
comparison between areas over the same period of
time. One of the key weaknesses in the model is that
South London is the only area where data were avail-
able on what impact the changes had on functioning
using the Barthel index. Instead, we had to make the
conservative estimate that the same improvement in
functioning was seen throughout the whole country
over the same time period. If we assume that instead
the improvements are the direct result of the reconfi-
gurations, the sensitivity analysis showed that the
London and GM models have a significantly higher
probability of being cost-effective.
A further limitation of the study is that we were
unable to calculate a ward-specific probability of being
discharged. As a result, some wards may have had higher
or lower LOS than in real life. However, the main ward
this will have had an impact on is the intensive therapy
unit (ITU), as it has a higher cost and lower utility score
than other wards. Nevertheless, there were only a small
percentage of people admitted to ITU and hence it is
unlikely to have had a significant impact on the results.
In one of the sensitivity analyses, we increased the
percentage of people admitted to ITU with little impact
on the results.
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Conclusions
Economic factors are a significant determinant in the
decision to implement major system change [27], but
the results of economic evaluations of centralisation are
rarely reported in a way that is helpful to decision-
makers [7]. How the results of economic evaluations are
reported may have a significant impact on the decision
to implement change and how a service should be
reconfigured. Although a centralised model of stroke
care across an entire metropolitan area has a high prob-
ability of being a cost-effective way to improve outcomes
for stroke patients at the threshold of £30,000 per QALY,
what this model of stroke care should look like is
dependent on the priorities of a decision-maker. If the
aim of the payer is to maximise clinical outcomes with
no consideration of budget, then the London model may
be the preferable one. In the context of fixed health bud-
gets, there is the potential that the additional cost of
centralisation may displace benefits of other services that
potentially produce more QALYs for a lower cost. In the
case of GM, it may be that the reconfigurations resulted
in a net health benefit to the health economy as a result
of the reduced cost per stroke even though they did not
result in additional clinical improvements.
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